IPP Bureau
Cipla incorporates JV company in USA
By IPP Bureau - March 02, 2024
Cipla completes transfer of Generics Business Undertaking
.jpg "Suven announces merger of Cohance Lifesciences")
Suven announces merger of Cohance Lifesciences
By IPP Bureau - March 01, 2024
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Biocon Biologics secures US market entry date for Bmab 1200
By IPP Bureau - March 01, 2024
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Briefs: Eugia Pharma Specialities and Eugia SEZ
By IPP Bureau - March 01, 2024
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Pfizer Oncology hosts innovation day
By IPP Bureau - March 01, 2024
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Bajaj Healthcare enters into definitive CDMO Agreement for 15 APIs with UK/EU customers
By IPP Bureau - February 29, 2024
BHL will undertake the development and supply of these molecules
TechInvention Lifecare breaks ground of its GCMC
By IPP Bureau - February 29, 2024
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
_in_Mizushima,_Japan.jpg "Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less")
Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less
By IPP Bureau - February 29, 2024
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
Chemex Global inaugurates state-of-the-art API plant in Guwahati
By IPP Bureau - February 29, 2024
The plant will drive pharmaceutical innovation in the Northeastern India
Bristol Myers Squibb inaugurates new US$100 million facility in Hyderabad
By IPP Bureau - February 28, 2024
The facility will accommodate over 1,500 employees
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions with food allergies
By IPP Bureau - February 28, 2024
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows achieved groundbreaking results in liver disease due to MASH
By IPP Bureau - February 28, 2024
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
NIA signs MoU with Department of Thai Traditional and Alternative Medicine
By IPP Bureau - February 28, 2024
MoU to serve as the establishment of an Academic Collaboration in Ayurveda and Thai Traditional Medicine
Ministry of Ayush signed MoU with Research and Information System for Developing Countries
By IPP Bureau - February 28, 2024
Academic and Policy Research to get further boost, RIS will bring forth Ayush Service Sector report soon
ABHA based Scan and Share Service facilitates 2 Crore instant OPD registrations nationwide
By IPP Bureau - February 28, 2024
Patients visiting OPD sections of hospitals use their Ayushman Bharat Health Account (ABHA) to get instant tokens to save time spent in registration queues
